neutral
1 day agoStrong listing pop lifts Corona Remedies as IPO investors log hefty gains
Corona Remedies made an impressive stock market debut on Monday, listing at a sharp premium on both exchanges. The shares opened at ₹1,470 on the NSE and ₹1,452 on the BSE, translating into gains of over 36 percent compared with the IPO price of ₹1,062. The ₹655.68 crore offer-for-sale issue had seen heavy demand across investor categories. Allotted investors earned about ₹20,580 per lot, reflecting strong appetite for the pharmaceutical company’s business profile.
Upstox• By Pooja Kumari
Explore:High Return Equity Mutual Fund
neutral
1 day agoStrong listing pop lifts Corona Remedies as IPO investors log hefty gains
Corona Remedies made an impressive stock market debut on Monday, listing at a sharp premium on both exchanges. The shares opened at ₹1,470 on the NSE and ₹1,452 on the BSE, translating into gains of over 36 percent compared with the IPO price of ₹1,062. The ₹655.68 crore offer-for-sale issue had seen heavy demand across investor categories. Allotted investors earned about ₹20,580 per lot, reflecting strong appetite for the pharmaceutical company’s business profile.
Upstox• By Pooja Kumari
Explore:Mutual Fund Screening
1 min read
73 words
Corona Remedies debuted strongly on the bourses with a 36–38 percent premium, delivering over ₹20,000 gains per lot to IPO investors.
Corona Remedies made an impressive stock market debut on Monday, listing at a sharp premium on both exchanges. The shares opened at ₹1,470 on the NSE and ₹1,452 on the BSE, translating into gains of over 36 percent compared with the IPO price of ₹1,062. The ₹655.68 crore offer-for-sale issue had seen heavy demand across investor categories. Allotted investors earned about ₹20,580 per lot, reflecting strong appetite for the pharmaceutical company’s business profile.
Corona Remedies made an impressive stock market debut on Monday, listing at a sharp premium on both exchanges. The shares opened at ₹1,470 on the NSE and ₹1,452 on the BSE, translating into gains of over 36 percent compared with the IPO price of ₹1,062. The ₹655.68 crore offer-for-sale issue had seen heavy demand across investor categories. Allotted investors earned about ₹20,580 per lot, reflecting strong appetite for the pharmaceutical company’s business profile.
Dec 15, 2025 • 06:40